Actelion Pharmaceuticals UK Ltd declared that Tracleer® (bosentan), a threefold endothelin organ antagonist, has been authorised in the UK and island for the change of the sort of newborn digital ulcers (DUs) in patients with systemic induration (SSc) and current DU disease.1DUs are a frequent, extremely agonized and unhealthful complexness of SSc2, caused by a low murder line to the fingers and toes.